Abstract

BackgroundMuscular dystrophies (MDs) are inherited diseases in which a dysregulation of the immune response exacerbates disease severity and are characterized by infiltration of various immune cell types leading to muscle inflammation, fiber necrosis and fibrosis. Immunosuppressive properties have been attributed to mesenchymal stem cells (MSCs) that regulate the phenotype and function of different immune cells. However, such properties were poorly considered until now for adult stem cells with myogenic potential and advanced as possible therapeutic candidates for MDs. In the present study, we investigated the immunoregulatory potential of human MuStem (hMuStem) cells, for which we previously demonstrated that they can survive in injured muscle and robustly counteract adverse tissue remodeling.MethodsThe impact of hMuStem cells or their secretome on the proliferative and phenotypic properties of T-cells was explored by co-culture experiments with either peripheral blood mononucleated cells or CD3-sorted T-cells. A comparative study was produced with the bone marrow (BM)-MSCs. The expression profile of immune cell-related markers on hMuStem cells was determined by flow cytometry while their secretory profile was examined by ELISA assays. Finally, the paracrine and cell contact-dependent effects of hMuStem cells on the T-cell-mediated cytotoxic response were analyzed through IFN-γ expression and lysis activity.ResultsHere, we show that hMuStem cells have an immunosuppressive phenotype and can inhibit the proliferation and the cytotoxic response of T-cells as well as promote the generation of regulatory T-cells through direct contact and via soluble factors. These effects are associated, in part, with the production of mediators including heme-oxygenase-1, leukemia inhibitory factor and intracellular cell adhesion molecule-1, all of which are produced at significantly higher levels by hMuStem cells than BM-MSCs. While the production of prostaglandin E2 is involved in the suppression of T-cell proliferation by both hMuStem cells and BM-MSCs, the participation of inducible nitric oxide synthase activity appears to be specific to hMuStem cell-mediated one.ConclusionsTogether, our findings demonstrate that hMuStem cells are potent immunoregulatory cells. Combined with their myogenic potential, the attribution of these properties reinforces the positioning of hMuStem cells as candidate therapeutic agents for the treatment of MDs.

Highlights

  • Muscular dystrophies (MDs) are inherited diseases in which a dysregulation of the immune response exacerbates disease severity and are characterized by infiltration of various immune cell types leading to muscle inflammation, fiber necrosis and fibrosis

  • While the production of prostaglandin E2 is involved in the suppres‐ sion of T-cell proliferation by both human MuStem (hMuStem) cells and Bone marrow-derived mesenchymal stem cell (BM-: Mesenchymal stem cell (MSC)), the participation of inducible nitric oxide synthase activity appears to be specific to hMuStem cell-mediated one

  • Results hMuStem cells display a poorly immunogenic and immunosuppressive phenotype To determine whether the hMuStem cells display an immunosuppressive phenotype similar to bone marrow (BM)-MSCs [33, 73, 74], we assessed the expression of human leukocyte antigen (HLA)-I and -II, as well as molecules involved in T-cell interaction

Read more

Summary

Introduction

Muscular dystrophies (MDs) are inherited diseases in which a dysregulation of the immune response exacerbates disease severity and are characterized by infiltration of various immune cell types leading to muscle inflammation, fiber necrosis and fibrosis. The presence of muscle inflammation and a significant increase in the proportion of immune cells in dystrophic muscle reveals an essential functional role of the immune system in the pathogenesis of MD [6, 7] This association was initially supported by studies demonstrating that glucocorticosteroid-mediated immunosuppression limits clinical signs and delays the course of DMD in patients and animal models [8, 9]. Accumulation of regulatory T cells (Tregs) has been demonstrated in infiltrates in muscle tissue from DMD patients [17], mdx mice [17, 18] and dysferlin-deficient mice [19] These findings highlight the therapeutic importance of regulating the infiltration and accumulation of immune cells in dystrophic muscle, both of which contribute to disease progression and severity

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.